One of the characteristics of chronic hepatitis B virus (HBV) infection is T-cell exhaustion, which, in turn, is mediated by the PD-1/PD-L1 axis. Researchers at Oligo Therapeutics Inc. reported on ALG-072571, a potent siRNA PD-L1 inhibitor active against HBV infection mouse models.
Recent studies in chronic hepatitis B patients have shown that bepirovirsen, an antisense oligonucleotide (ASO), may be considered a suitable option for the treatment of hepatitis B virus (HBV) infection.
Current therapeutic options for chronic hepatitis B virus (HBV) are not effective for all patient subsets and, due to their lack of specificity, often provoke toxicity and off-target effects. CD8+ T cells are essential in the fight against viruses but in chronically HBV-infected patients, these cells become unproductive and difficult to detect. At the recent Annual Meeting of the European Association for the Study of the Liver (EASL), Matteo Iannacone, professor of Pathology and Immunology from IRCCS San Raffaele in Milano, presented a novel interleukin 2 (IL-2)-based immunotherapy approach that used a modular cis-targeting platform to tackle HBV infection specifically in patients suffering from chronic viral infection.
At the ongoing European Association for the Study of the Liver meeting, researchers from Suzhou Ribo Life Science Co. Ltd. presented preclinical data on RBD-1016 in two models of chronic hepatitis B virus (HBV) infection.
Clevudine derivatives and its phosphoramidates have been detailed in an Emory University patent as potentially useful for the treatment of hepatitis B virus (HBV) infection.
Zhimeng Biopharma Inc. found a global partner for its hepatitis B virus (HBV) program, licensing rights to GSK plc for CB-06, an oral small-molecule Toll-like receptor 8 agonist. Pending positive data from an ongoing phase I study, GSK will gain rights to develop, manufacture and commercialize the drug for chronic HBV infection, either for use in combination or as a sequential treatment with bepirovirsen.
Zhimeng Biopharma Inc. found a global partner for its hepatitis B virus (HBV) program, licensing rights to GSK plc for CB-06, an oral small-molecule Toll-like receptor 8 agonist. Pending positive data from an ongoing phase I study, GSK will gain rights to develop, manufacture and commercialize the drug for chronic HBV infection, either for use in combination or as a sequential treatment with bepirovirsen.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has presented HBeAg (hepatitis B virus; HBV) and/or HBsAg (HBV) secretion inhibitors reported to be useful for the treatment of HBV infections.
